https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/dr-wendy-heywood-awarded-investigator-initiated-research-proposal-shire-pharmaceuticals/
Dr Wendy Heywood awarded investigator initiated research proposal from Shire Pharmaceuticals
28 Jun 2016, 2:01 p.m.
Following NIHR Great Ormond Street BRC support, which led to the creation of a high-throughput targeted proteomic urine test, Dr Wendy Heywood has been awarded an industry investigator initiated award from Shire Pharmaceuticals.
This award is for a Great Ormond Street Hospital (GOSH) research nurse to facilitate the clinical sample collection pipeline and manage a database of patient samples and clinical information. This Rare Disease Sample Collection will allow researchers at the UCL Institute of Child Health (ICH) and clinicians from the GOSH Metabolic disease clinic, to find new biomarkers, new disease mechanisms, design new treatments and test patients.
This streamlined ICH-GOSH collaboration will enable translation of current and future new metabolic disease biomarkers to clinical laboratories for use in future clinical trials of existing and novel therapies.
Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery
The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
GOSH only hospital outside of North America to receive innovation funding award for AI
GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)